Nilotinib is a targeted cancer medicine (biological therapy) and also called Tasigna , the trade name of nilotinib Tasigna is cancer drugs, which interfere with growth of the cancer cells. Tasigna is a prescription medicine, which is used under the knowledge of medical oncologist. The safety and efficacy of the medicine Tasigna in children younger than 1 year has not been established Tasigna is comes under the group of kinase inhibitors.
Tasigna tablets are primarily indicated in the conditions like; Adults with chronic and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML) resistant or intolerant to prior therapy that included Imatinib
Generally the recommended dose of Tablet Tasigna should be taken as twice daily at time intervals of 12 hours. Tasigna must be taken on an empty stomach Food should not be taken for at least 1 hour after the dose is taken or 2 hours before the dose is taken The patients, who are unable to taken the Tasigna capsules, should be dispersed in one teaspoon of applesauce. This mixture should be taken immediately within 15 minutes Tasigna should be concomitant with hematopoietic growth factors such as erythropoietin or G-CSF Also with hydroxyurea or anagrelide
The bioavailability of Tasigna tablets are about 50% The peak plasma concentration of Tasigna tablet is occurred within 3 hours after administration.
Effect of food:
While compared to fasted patient, the effect of drug is increased to 82% when the dose was given 30 minutes after a high fat meal
The serum protein binding of the Tasigna is approximately 98% The blood to serum ratio of Nilotinib is 0.68
Tasigna is metabolized through CYP3A4 mediated oxidation Nilotinib is the prime circulating component in the blood stream
The terminal half life period of Tablet Tasigna is approximately 17 hours The mean apparent clearance value is 29L/hr
The prescribed dose of the Tasigna tablet in this condition is 300mg should be given orally as twice daily.
The prescribed dose is 400mg should be administered as orally twice daily
chronic myelogenous leukemia is caused by BCR-ABL oncogene Tasigna (nilotinib) is a kinase inhibitor, which prohibits BCR-ABL kinase activity
Tasigna bind to the ATP-binding site of BCR-ABL protein Tasigna prohibits multiplication of murine leukemic cell lines and human cell lines derived from patients with Philadelphia positive CML
The recommended dose 230mg/m2 should be given orally twice daily
|BSA (body surface area)||Single dose||Total daily dose|
|Up to 0.32 m2||50 mg||100mg|
|0.33 to 0.54 m2||100mg||200mg|
|0.55 to 0.76 m2||150mg||300mg|
|0.55 to 0.76 m2||150mg||300mg|
|0.77 to 0.97 m2||200mg||400mg|
|0.98 to 1.19 m2||250mg||500mg|
|1.20 to 1.41 m2||300mg||600mg|
|1.42 to 1.63 m2||350mg||700mg|
Tasigna (nilotinib) side effects are given below,
Rash, Pruritus, alopecia, dry skin
Nausea, constipation, diarrhea, vomiting, upper abdominal pain, dyspepsia
Fatigue, pyrexia, asthenia, peripheral edema, face edema
Myalgia, arthralgia, muscle spasm, pain in extremity, back pain
Cough, oropharyngeal pain, dyspnea
Infections & infestations:
Nasopharyngitis, upper respiratory tract infection, influenza, gastroenteritis
Eye:Eyelid edema, periorbital edema
Tasigna While concomitant with strong CYP3A inhibitors leads to increase Nilotinib concentrations compared to while using Tasigna alone Tasigna Concomitant with strong CYP3A inducer leads to reduce Nilotinib concentration Tasigna With proton pump inhibitors: reduce Tasigna efficacy Avoid concomitant of Tasigna with drugs that may prolong the QT interval like anti-arrhythmic drugs
Tasigna may cause thrombocytopenia, neutropenia and anemia, so check blood counts periodically to reduce these complications Care should be take while using Tasigna in patient who are suffered with Hypokalemia, Hypomagnesemia, Long QT syndrome, Pancreatitis and elevated lipase, Hepatotoxicity, Electrolyte abnormalities, Tumor lysis syndrome.
If patients fails to administer the dose of Tasigna should be take within the time, otherwise the missed dose should be skipped and follow the next dosing schedule.
Pregnancy category: D Tasigna should not be used in pregnancy condition and women who become pregnant Tasigna not recommended in breastfeeding mothers
Tasigna tablets should be stored at room temperature between 68oF to 77oF (20oC to 25oC) Tasigna container should be keep away from heat, moisture and light
Tasigna do not used in the patients who are having; Hypokalemia Hypomagnesemia Long QT syndrome
1. Anti-Cancer-Drugs.com, a fully licensed and regulated pharmacy, takes all precautions to strictly abide by the laws and regulations set forth in the dispensing of prescription medications. By placing the order for your prescription medicines, you acknowledge and accept the following terms regarding the purchase of any prescription medicines.
2. Anti-Cancer-Drugs.com will not dispense any prescription medication without a valid prescription from a licensed physician.
3. If you are ordering prescription medication(s), you hereby confirm that you will send us a scanned copy of your valid prescription(s) via email, fax, Whatsapp, or by post, and this prescription shall then be subject to the scrutiny of and approval by our qualified Pharmacists.
4. The drug information provided in the Anti-Cancer-Drugs.com is for informative purposes only and this Website is not intended to provide diagnosis, treatment or medical advice. We are not liable for any adverse effects or harm to you as a result of your reliance on the information in the Website.
5. Anti-Cancer-Drugs.com requires either the User or Customer or the Caregiver to confirm he/she is completely aware of the indications, side effects, drug interactions, effects of missed dose or overdose of the medicines he/she orders from us. It is imperative to seek professional advice from your physician before purchasing or consuming any medicine from Anti-Cancer-Drugs.com
6. At Anti-Cancer-Drugs.com, a Caregiver can order prescription medicines on your behalf.